HTC
VRTX icon

Haverford Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Haverford Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-663
Closed -$296K – 442
2026
Q1 		$296K Sell
663
-77
-10% -$35.9K ﹤0.01% 367
2025
Q4 		$335K Buy
+740
New +$319K ﹤0.01% 347
2025
Q3 		– Sell
-463
Closed -$206K – 417
2025
Q2 		$206K Buy
+463
New +$213K ﹤0.01% 396

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Haverford Trust Company's VRTX Position: Q2 2026 in Review

Haverford Trust Company sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 663 shares — an estimated $296K sold.

Haverford Trust Company first reported a position in VRTX in Q2 2025 and held it in 3 quarters. The position peaked at $335K in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Haverford Trust Company reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Haverford Trust Company sold 663 Vertex Pharmaceuticals shares in Q2 2026, an estimated $296K.
  • Haverford Trust Company first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Haverford Trust Company's Vertex Pharmaceuticals position peaked at $335K in Q4 2025.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Haverford Trust Company's 13F filing for Q2 2026, filed 12 Aug 2026.